@JTLonsdale: 1/ US biotech is in crisis, right before AI should be saving millions. China is stealing away our industry and has surp…
Summary
US biotech is in crisis as China surpasses the US in blockbuster pharma deals; the next FDA Commissioner must overhaul the agency and beat China to unleash cures.
View Cached Full Text
Cached at: 06/02/26, 01:40 AM
1/ US biotech is in crisis, right before AI should be saving millions.
China is stealing away our industry and has surpassed the US in blockbuster pharma deals.
The next FDA Commissioner must be a fighter, and have a plan to overhaul the agency, beat China, and unleash cures.
2/ America should be the fastest, safest place in the world to deploy clinical AI & get promising cures to patients.
Instead, we are suffocating innovation with a top-down, Soviet-style bureaucracy.
Here are some table stakes for the next FDA leader:
Thanks, Patrick!
You are doing inspiring work in biotech for our civilization, that means a lot coming from you.
If you read the piece you’ll see we understand the speed issue.
But what you might not understand is that unless the next FDA leader is very bold - and yes, a fighter - the sclerotic bureaucracy will over-rule and ignore and outlast her, resisting smarter and faster processes.
I am careful with my words. I have seen many sketchy and purposeful unethical actions to steal away economic activity and to copy and get around patents (and then fast track approval).
That doesn’t mean there isn’t also impressive work going on in China.
But it’s both.
He’s obviously a terrible and hateful guy, on so many levels, bringing in third world base envy as a core campaign value and having a tattoo of the worst is the Nazis, that if you support him you are completely lost about what will help lift up lives in our civilization.
My 15 year-old self might agree with you ;).
Better private solutions could evolve.
But we have to work towards the best solution within the constraints of what’s achievable in our republic as it stands with the laws of the land and the views of Congress, and what CAN get done.
Thanks for this @JTLonsdale — I’ve been having an exhausting argument with biotech VCs for the last week about not offshoring biotech R&D to cheaper scientific labor in China. Sort of getting nowhere I don’t know if it’s possible for tech folks to give a warning about the stupidity of Sequoia China, etc, so we don’t have to learn all this the hard way in biotech:
https://x.com/jrkelly/status/2058368999709184161?s=46…
Biotech is in existential crisisAnyone, who says it’s not is, is having his or her head buried in the sand. It’s my conclusion from running a startup company in both& up to P2 trials since 2011. @JTLonsdale @PeterKolchinsky @jrkelly @pharmabro0782 @JMaraganore @rtnarch
Biotech is an area where you spend billions on research and trials. If somebody can just take and use the results, then you can’t justify the investment next time.
Don’t be retarded.
This is one of the few areas where IP allows our civilization to invest and advance.
Also this part is real
You’re SPOT ON @JTLonsdale ! Thanks for articulating all this so well.
Similar Articles
@RuxandraTeslo: We are on the cusp of a wave of new therapies for some of the worst diseases. But the world won’t benefit unless the US…
This essay argues that slow and costly U.S. clinical trials—not scientific limitations—are now the biggest obstacle to curing cancer and deploying AI-driven personalized therapies, urging regulatory reform as China and Australia outpace American drug development.
@agupta: I agree with @JTLonsdale on these suggestions. I’ll add one more. aggressively expand the most successful public-privat…
In a thread, @agupta agrees with @JTLonsdale's suggestions on the US biotech crisis and adds that the US should aggressively expand the research university system and 10x NIH and NSF budgets to leverage AI.
The U.S. lead over China in AI is all but gone.
Op-ed arguing that the U.S. lead over China in AI has largely evaporated, and that Washington must shift from reacting to Chinese breakthroughs to shaping the competitive environment across the full innovation ecosystem.
NYT: Protect America’s lead in the A.I. race.
A critical take on a New York Times editorial that argues the US should maintain its AI lead by restricting chip sales to China, with the commenter accusing the Times of America-first bias.
Why AI race with US is a ‘knockout game’ China cannot afford to lose
A Chinese academic warns that China must fundamentally overhaul its innovation ecosystem to avoid losing a geopolitical AI 'knockout game' against the US, advocating for open-source AI and shifting foundational research from universities to leading tech enterprises.